Cost-effectiveness of apixaban versus other oral anticoagulants and aspirin for stroke prevention in atrial fibrillation in indian subcontinent

被引：1
|
作者：
Kulkarni, N. [1 ]
Taur, S. [1 ]
Tichy, E. [2 ]
Kongnakorn, T. [3 ]
Sharma, R. [4 ]
机构：
[1] Pfizer India, Med Affairs, Mumbai, Maharashtra, India
[2] Evidera, Budapest, Hungary
[3] Evidera, London, England
[4] Fortis Hosp, Mohali, India
来源：
EUROPEAN HEART JOURNAL | 2022年 / 43卷
关键词：
D O I：
10.1093/eurheartj/ehab849.022
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Systematic review of cost-effectiveness analyses of novel oral anticoagulants for stroke prevention in atrial fibrillation
    Ferreira, Joao
    Mirco, Ana
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2015, 34 (03) : 179 - 191
  • [22] Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation
    Singh, Sheldon M.
    Wijeysundera, Harindra C.
    CURRENT CARDIOLOGY REPORTS, 2015, 17 (08)
  • [23] Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence
    Lanitis, Tereza
    Leipold, Robert
    Hamilton, Melissa
    Rublee, Dale
    Quon, Peter
    Browne, Chantelle
    Cohen, Alexander T.
    CLINICAL THERAPEUTICS, 2016, 38 (03) : 478 - 493
  • [24] Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation
    Lip, Gregory Y. H.
    Lanitis, Tereza
    Kongnakorn, Thitima
    Phatak, Hemant
    Chalkiadaki, Corina
    Liu, Xianchen
    Kuznik, Andreas
    Lawrence, Jack
    Dorian, Paul
    CLINICAL THERAPEUTICS, 2015, 37 (11) : 2476 - 2488
  • [25] Cost-Effectiveness of Apixaban Compared to Other New Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation
    Rudakova, A. V.
    Tatarskiy, B. A.
    KARDIOLOGIYA, 2014, 54 (07) : 43 - 52
  • [26] Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
    Harrington, Amanda R.
    Armstrong, Edward P.
    Nolan, Paul E., Jr.
    Malone, Daniel C.
    STROKE, 2013, 44 (06) : 1676 - +
  • [27] Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation
    Kamel, Hooman
    Easton, J. Donald
    Johnston, S. Claiborne
    Kim, Anthony S.
    NEUROLOGY, 2012, 79 (14) : 1428 - 1434
  • [28] COST-EFFECTIVENESS ANALYSIS OF APIXABAN COMPARED TO OTHER DOACS FOR PREVENTION OF STROKE IN AUSTRIAN ATRIAL FIBRILLATION PATIENTS
    Walter, E.
    Voit, M.
    Eichhober, G.
    VALUE IN HEALTH, 2019, 22 : S548 - S548
  • [29] Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium
    Thitima Kongnakorn
    Tereza Lanitis
    Lievens Annemans
    Vincent Thijs
    Sophie Marbaix
    Clinical Drug Investigation, 2014, 34 : 709 - 721
  • [30] Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium
    Kongnakorn, Thitima
    Lanitis, Tereza
    Annemans, Lievens
    Thijs, Vincent
    Marbaix, Sophie
    CLINICAL DRUG INVESTIGATION, 2014, 34 (10) : 709 - 721
12345